HENLIUS (02696) announced that the first patient in China (excluding Hong Kong, Macau, and Taiwan) has been dosed in a Phase 1b/2 clinical study. The trial is evaluating the combination of HLX43 (a targeted PD-L1 antibody-drug conjugate) with either HLX07 (a recombinant anti-EGFR humanized monoclonal antibody injection) or Hansizhuang® (serplulimab injection) in patients with advanced or metastatic colorectal cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.